Connect with us

The Considered pharmaceutical marketing experiment

COVID-19 has changed everything – at least that’s David Hunt’s plan for pharmaceutical marketing. The former CEO of
The post The Considered pharmaceutical marketing experiment appeared first on .

Published

on

COVID-19 has changed everything – at least that’s David Hunt’s plan for pharmaceutical marketing. The former CEO of Havas Lynx recently launched a new agency in the US called The Considered, with the intent to break the traditional pharma marketing rules and shake up the industry.

“There is some brilliant work that takes place by some incredibly intelligent agencies and individuals, but I know how formulaic we’ve become as an industry where next year’s tactics are probably very similar to this year’s tactics,” he says. “What we want to drive and hopefully bring change in the industry is a far greater appetite for experimentation, innovation, more empathetic and more data-powered creative and just miles better products.”

The experiment, as Hunt puts it, to do pharma marketing differently has been borne out of the COVID-19 pandemic. The industry has been “elevated to hero status” following the accelerated development of safe and effective vaccines, Hunt says, which provides an opportunity for pharma to harness the love and make a real impact for patients. But this involves changing in line with the rest of the world and doing things differently.

“The way that pharma builds brands, builds relationships, builds rapport, and drives communications, post-COVID that feels like it absolutely has to change and has to change significantly,” he says. “That formula and method that was taking place before the pandemic, that we know was getting less and less effective, now dramatically has to change.

“It’s no longer enough to just keep dialling up your media spend, adding a couple more boots on the ground or driving extra 1% and marginal gains from an existing formula. It’s time for fresh thinking, breaking rules and a different approach to communications.”

Resetting the dial

Pharma has tended to follow a shopping list of e-details, TV and print ads, explains The Considered CCO Pete Armstrong, who led one of the world’s largest data-driven creative communication campaigns for the US military. While the “old way of doing things” isn’t broken per-se, he says the pandemic has provided an opportunity to “reset the dial”.

Namely, the pandemic has forced people to embrace innovation, data, and technology. For example, people in their 80s using Zoom and doctor’s consultations going online. According to Armstrong, now it’s time for pharma to do the same with its marketing and tap into people’s new digital behaviours.

“It’s odd for me that pharma scientists embrace data, failure, and experimentation but on the pharma communication side, it doesn’t embrace experimentation as often as it should,” he says. “There are so many opportunities, adjacent technologies and data out there right now that I don’t think pharma’s even touched on.”

Essentially, The Considered is about solving creative challenges, bringing in fresh ways of thinking and of doing things explains Hunt. Part of that has been the creation of pharma’s first global Clubhouse community Health.Reconsidered. The platform is a forum led by patients and patient advocates to discuss their challenges and desires about health in the US.

Hunt says it has been fascinating hearing perspectives different to pharma and agencies. A notable item from the discussions was around the common, but outdated, thinking that the biggest, boldest creative idea was best. “One thing that’s come from these conversations is maybe the healthcare professionals and patients don’t want the biggest and boldest idea. Maybe they don’t want a rocket to get to the moon. Maybe they just want a telescope to see it.”

Hunt says glitz and glam have their place, but post-pandemic, it’s about having the right ideas for the right people to have the right impact. Armstrong agrees. “We are going to focus on using data and how we can change behaviours through innovation rather than default to a TV ad or an e-detail, and we want to focus on changing behaviour before we focus on doing standout creative work.”

It’s a shift that places the patient and positive impact firmly at the centre rather than focusing on financial gain. “What do people really remember you for?” asks Armstrong. “They don’t remember you for your job title or your salary bracket. They remember you for some form of good that you do and the legacy you leave or rather the eulogy virtues.

“That’s where this turning point is for us. From a creative point of view, I think pharma communications needs a better bedside manner, so how do we put people and think of patients as people – emotionally complex individuals rather than biomedical entities – at the heart of everything we do?”

Creating an appetite for change

To create this change in the industry, Hunt has brought together a team of “pioneers”, as he calls them. Alongside data-guru Armstrong on the leadership team, there’s Professor Shafi Ahmed, an award-winning cancer surgeon who was the first surgical instructor to use Google Glass to perform and stream a live operation to 14,000 students in 132 countries.

The Considered is also partnering with the likes of Alex Butler who spearheaded pharma’s first social media campaign, Psoriasis360, and search expert Matt Lowe. It is also harnessing the global creative talent pool of several billion people to unlock the benefits of a hybrid working model.

“What I love about the creative team Pete is assembling from around the world is I literally don’t understand them – they exist in completely different cultures to me,” Hunt says. “I love the fact it’s uncommon experiences and inconsistent points of view, and with that comes incredibly rich creative ideas that otherwise we wouldn’t have had.”

But is there really an appetite in pharma to do things differently? Hunt says both yes and no. But that’s fine as he only wants to work with forward-thinking companies that want fresh ideas and new ways of doing things.

“The Considered is totally an experiment and I think it’s a really considered experiment based on years and years of experience. We see this as a journey, and we want to be pioneers on that journey.”

Indeed, he believes change in the industry is inevitable. “How fast though depends on brilliant creative talent being freed to be brilliant,” he says. “That’s my reason to be.”

The post The Considered pharmaceutical marketing experiment appeared first on .

Read More

Continue Reading

Uncategorized

Aging at AACR Annual Meeting 2024

BUFFALO, NY- March 11, 2024 – Impact Journals publishes scholarly journals in the biomedical sciences with a focus on all areas of cancer and aging…

Published

on

BUFFALO, NY- March 11, 2024 – Impact Journals publishes scholarly journals in the biomedical sciences with a focus on all areas of cancer and aging research. Aging is one of the most prominent journals published by Impact Journals

Credit: Impact Journals

BUFFALO, NY- March 11, 2024 – Impact Journals publishes scholarly journals in the biomedical sciences with a focus on all areas of cancer and aging research. Aging is one of the most prominent journals published by Impact Journals

Impact Journals will be participating as an exhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2024 from April 5-10 at the San Diego Convention Center in San Diego, California. This year, the AACR meeting theme is “Inspiring Science • Fueling Progress • Revolutionizing Care.”

Visit booth #4159 at the AACR Annual Meeting 2024 to connect with members of the Aging team.

About Aging-US:

Aging publishes research papers in all fields of aging research including but not limited, aging from yeast to mammals, cellular senescence, age-related diseases such as cancer and Alzheimer’s diseases and their prevention and treatment, anti-aging strategies and drug development and especially the role of signal transduction pathways such as mTOR in aging and potential approaches to modulate these signaling pathways to extend lifespan. The journal aims to promote treatment of age-related diseases by slowing down aging, validation of anti-aging drugs by treating age-related diseases, prevention of cancer by inhibiting aging. Cancer and COVID-19 are age-related diseases.

Aging is indexed and archived by PubMed/Medline (abbreviated as “Aging (Albany NY)”), PubMed CentralWeb of Science: Science Citation Index Expanded (abbreviated as “Aging‐US” and listed in the Cell Biology and Geriatrics & Gerontology categories), Scopus (abbreviated as “Aging” and listed in the Cell Biology and Aging categories), Biological Abstracts, BIOSIS Previews, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).

Please visit our website at www.Aging-US.com​​ and connect with us:

  • Aging X
  • Aging Facebook
  • Aging Instagram
  • Aging YouTube
  • Aging LinkedIn
  • Aging SoundCloud
  • Aging Pinterest
  • Aging Reddit

Click here to subscribe to Aging publication updates.

For media inquiries, please contact media@impactjournals.com.


Read More

Continue Reading

Government

Mathematicians use AI to identify emerging COVID-19 variants

Scientists at The Universities of Manchester and Oxford have developed an AI framework that can identify and track new and concerning COVID-19 variants…

Published

on

Scientists at The Universities of Manchester and Oxford have developed an AI framework that can identify and track new and concerning COVID-19 variants and could help with other infections in the future.

Credit: source: https://phil.cdc.gov/Details.aspx?pid=23312

Scientists at The Universities of Manchester and Oxford have developed an AI framework that can identify and track new and concerning COVID-19 variants and could help with other infections in the future.

The framework combines dimension reduction techniques and a new explainable clustering algorithm called CLASSIX, developed by mathematicians at The University of Manchester. This enables the quick identification of groups of viral genomes that might present a risk in the future from huge volumes of data.

The study, presented this week in the journal PNAS, could support traditional methods of tracking viral evolution, such as phylogenetic analysis, which currently require extensive manual curation.

Roberto Cahuantzi, a researcher at The University of Manchester and first and corresponding author of the paper, said: “Since the emergence of COVID-19, we have seen multiple waves of new variants, heightened transmissibility, evasion of immune responses, and increased severity of illness.

“Scientists are now intensifying efforts to pinpoint these worrying new variants, such as alpha, delta and omicron, at the earliest stages of their emergence. If we can find a way to do this quickly and efficiently, it will enable us to be more proactive in our response, such as tailored vaccine development and may even enable us to eliminate the variants before they become established.”

Like many other RNA viruses, COVID-19 has a high mutation rate and short time between generations meaning it evolves extremely rapidly. This means identifying new strains that are likely to be problematic in the future requires considerable effort.

Currently, there are almost 16 million sequences available on the GISAID database (the Global Initiative on Sharing All Influenza Data), which provides access to genomic data of influenza viruses.

Mapping the evolution and history of all COVID-19 genomes from this data is currently done using extremely large amounts of computer and human time.

The described method allows automation of such tasks. The researchers processed 5.7 million high-coverage sequences in only one to two days on a standard modern laptop; this would not be possible for existing methods, putting identification of concerning pathogen strains in the hands of more researchers due to reduced resource needs.

Thomas House, Professor of Mathematical Sciences at The University of Manchester, said: “The unprecedented amount of genetic data generated during the pandemic demands improvements to our methods to analyse it thoroughly. The data is continuing to grow rapidly but without showing a benefit to curating this data, there is a risk that it will be removed or deleted.

“We know that human expert time is limited, so our approach should not replace the work of humans all together but work alongside them to enable the job to be done much quicker and free our experts for other vital developments.”

The proposed method works by breaking down genetic sequences of the COVID-19 virus into smaller “words” (called 3-mers) represented as numbers by counting them. Then, it groups similar sequences together based on their word patterns using machine learning techniques.

Stefan Güttel, Professor of Applied Mathematics at the University of Manchester, said: “The clustering algorithm CLASSIX we developed is much less computationally demanding than traditional methods and is fully explainable, meaning that it provides textual and visual explanations of the computed clusters.”

Roberto Cahuantzi added: “Our analysis serves as a proof of concept, demonstrating the potential use of machine learning methods as an alert tool for the early discovery of emerging major variants without relying on the need to generate phylogenies.

“Whilst phylogenetics remains the ‘gold standard’ for understanding the viral ancestry, these machine learning methods can accommodate several orders of magnitude more sequences than the current phylogenetic methods and at a low computational cost.”


Read More

Continue Reading

International

There will soon be one million seats on this popular Amtrak route

“More people are taking the train than ever before,” says Amtrak’s Executive Vice President.

Published

on

While the size of the United States makes it hard for it to compete with the inter-city train access available in places like Japan and many European countries, Amtrak trains are a very popular transportation option in certain pockets of the country — so much so that the country’s national railway company is expanding its Northeast Corridor by more than one million seats.

Related: This is what it's like to take a 19-hour train from New York to Chicago

Running from Boston all the way south to Washington, D.C., the route is one of the most popular as it passes through the most densely populated part of the country and serves as a commuter train for those who need to go between East Coast cities such as New York and Philadelphia for business.

Veronika Bondarenko captured this photo of New York’s Moynihan Train Hall. 

Veronika Bondarenko

Amtrak launches new routes, promises travelers ‘additional travel options’

Earlier this month, Amtrak announced that it was adding four additional Northeastern routes to its schedule — two more routes between New York’s Penn Station and Union Station in Washington, D.C. on the weekend, a new early-morning weekday route between New York and Philadelphia’s William H. Gray III 30th Street Station and a weekend route between Philadelphia and Boston’s South Station.

More Travel:

According to Amtrak, these additions will increase Northeast Corridor’s service by 20% on the weekdays and 10% on the weekends for a total of one million additional seats when counted by how many will ride the corridor over the year.

“More people are taking the train than ever before and we’re proud to offer our customers additional travel options when they ride with us on the Northeast Regional,” Amtrak Executive Vice President and Chief Commercial Officer Eliot Hamlisch said in a statement on the new routes. “The Northeast Regional gets you where you want to go comfortably, conveniently and sustainably as you breeze past traffic on I-95 for a more enjoyable travel experience.”

Here are some of the other Amtrak changes you can expect to see

Amtrak also said that, in the 2023 financial year, the Northeast Corridor had nearly 9.2 million riders — 8% more than it had pre-pandemic and a 29% increase from 2022. The higher demand, particularly during both off-peak hours and the time when many business travelers use to get to work, is pushing Amtrak to invest into this corridor in particular.

To reach more customers, Amtrak has also made several changes to both its routes and pricing system. In the fall of 2023, it introduced a type of new “Night Owl Fare” — if traveling during very late or very early hours, one can go between cities like New York and Philadelphia or Philadelphia and Washington. D.C. for $5 to $15.

As travel on the same routes during peak hours can reach as much as $300, this was a deliberate move to reach those who have the flexibility of time and might have otherwise preferred more affordable methods of transportation such as the bus. After seeing strong uptake, Amtrak added this type of fare to more Boston routes.

The largest distances, such as the ones between Boston and New York or New York and Washington, are available at the lowest rate for $20.

Read More

Continue Reading

Trending